<DOC>
	<DOCNO>NCT01401868</DOCNO>
	<brief_summary>The purpose study determine tolerability ME-143 , find maximum tolerate dose , safety profile patient refractory solid tumor .</brief_summary>
	<brief_title>Phase I Dose Escalation Study Safety Pharmacokinetics ME-143 Single Agent Refractory Solid Tumors</brief_title>
	<detailed_description>The purpose study determine tolerability ME-143 , find maximum tolerate dose , dose limit toxicity , safety profile patient refractory solid tumor . In addition , study plan characterize pharmacokinetic profile ME-143 describe clinical anti-tumor activity observe patient .</detailed_description>
	<criteria>Provision inform consent Male female ≥18 year age Histologic cytologic confirm locally advanced metastatic cancer standard therapeutic alternative . ECOG Performance status 01 A minimum life expectancy 12 week Adequate bone marrow , hepatic renal function evidence Absolute neutrophil count ( ANC ) &gt; 1.5 x 109/L Platelet count &gt; 100 x 109/L Hemoglobin &gt; 9.0 g/dL Serum bilirubin &lt; 1.5 x ULN AST/ALT ( SGOT/SGPT ) &lt; = 2.5 x ULN reference laboratory &lt; 5 x ULN presence liver metastases Serum creatinine &lt; = 1.5 x ULN FollicleStimulating Hormone ( FSH ) within normal baseline level Male patient detectable level testosterone Female patient know capable conception negative serum pregnancy test ( betahuman chorionic gonadotropin βhCG ] ) within 1 week start study . All potentially fertile patient agree use effective form contraception study 90 day follow last dose ME143 ( effective form contraception define oral contraceptive double barrier method ) . At least 4 week must elapse prior Day 1 Cycle 1 since prior chemotherapy ( 6 week carmustine mitomycin C ) , investigational drug biologic therapy toxicity associate treatment recover ≤ NCICTCAE Grade 1 . At least 21 day must elapse prior Day 1 Cycle 1 , radiotherapy ( limited palliative radiation allow &gt; 2 week ) , immunotherapy follow major surgery surgical incision completely heal Patients pregnant breastfeed Tumor involvement Central Nervous System ( CNS ) Patients treat stable CNS metastasis may eligible participate discussion approval Medical Monitor Uncontrolled infection systemic disease . Clinically significant cardiac disease well control medication ( e.g. , congestive heart failure , symptomatic coronary artery disease e.g . angina , cardiac arrhythmia ) myocardial infarction within last 12 month . Patients QTc &gt; 470 msec screen ECG . ( If patient QTc interval &gt; 470 msec screen ECG , screen ECG may repeat twice ( least 24 hour apart ) . The average QTc 3 screen ECGs must &lt; 470 msec order patient eligible study . Any major surgery , radiotherapy , immunotherapy within last 21 day ( limited palliative radiation allow &gt; 2 week ) . Chemotherapy regimens delay toxicity within last 4 week ( within 6 week prior nitrosourea mitomycin C ) . Chemotherapy regimens give continuously weekly basis limit potential delayed toxicity within last 2 week . No concurrent systemic chemotherapy biologic therapy allow . Known hypersensitivity component ME143 study drug product . Known human immunodeficiency virus ( HIV ) Hepatitis B C ( active , previously treat ) . History solid organ transplantation . Psychiatric disorder social geographic situation would preclude study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>recurrent</keyword>
	<keyword>advanced</keyword>
	<keyword>metastatic</keyword>
</DOC>